Staging ::: VER CORREOS
España
Acceder

Farmas USA

136K respuestas
Farmas USA
86 suscriptores
Farmas USA
Página
9.462 / 17.039
#75690

Re: Farmas USA

Clinton backs Medicare negotiation, copay caps in assault on pharma pricing

The industry trade group PhRMA is on record against Medicare price negotiation, re-importation, et al. Responding to Sanders' proposals earlier this month, the organization said private payers can handle the job of pressuring drugmakers on prices. It also cited generic meds and their long-term effect on drug spending.
--

PhRMA hasn't yet addressed Clinton's ideas, but it took aim at the CAP plan, saying that it would stifle innovation and interfere with development of new meds by setting "arbitrary caps" on prices. Plus, it would "cost countless jobs," the group said.
-

http://www.fiercepharma.com/story/clinton-backs-medicare-negotiation-co-pay-caps-assault-pharma-pricing/2015-09-22?utm_medium=nl&utm_source=internal

#75692

Re: Farmas USA

Gracias. No lo sabía.

#75693

Re: Farmas USA

Ojala Framus... que rica seria esa morning star... veremos...

#75694

Re: Farmas USA

Top 25
anaramos

OCAT

Ocata to Present at Ladenburg Thalmann 2015 Healthcare Conference
Tuesday, September 29, 2015 at 1:30 p.m

http://ir.ocata.com/press-releases/detail/2798

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#75695

Re: Farmas USA

Top 25
anaramos

TIG

Esta ya tiene 200 millones de capitalización, así que cuelgo la noticia:

Resultados de seguridad positivos con grupo de control con placebo para las células cardíacas. La bomba es que además arrojan datos de efectividad (última frase). Habría que ir entrando en esta.

http://finance.yahoo.com/news/tigenix-allocsc-01-phase-data-050456890.html

• CAREMI dose-escalation open-label phase data presented at the Congress of the European Society of Cardiology (ESC) confirm the good safety profile of AlloCSC-01 in patients suffering from Acute Myocardial Infarction (AMI)
• AMI patients treated in the dose-escalation open-label phase showed a reduction in infarct size and improvement of left ventricular ejection fraction (LVEF) on Magnetic Resonance Imaging (MRI) after the administration of AlloCSC-01 over a six-month period
• CAREMI is a two phase study: an open-label dose-escalation phase and a randomised, double-blind, placebo-controlled phase, aiming at evaluating the safety and efficacy of intracoronary infusion of AlloCSC-01, a suspension of allogeneic human cardiac stem cells (CSC)
• Patients received a single injection of 11 million (M), 22M or 35M cells of AlloCSC-01 (n=2 each) by intracoronary infusion 5 to 7 days after Percutaneous Coronary Intervention (PCI). Data presented show that AlloCSC-01 has a good safety profile as no adverse events or Major Adverse Cardiac Events (MACE) were observed during the 6 month follow-up period. Of note, preliminary efficacy data showed a reduction in the infarct size, and a LVEF improvement on MRI, over the 6-month follow-up period (n=5; p<0.05 for both parameters)

Edito: el formato de negrita no va bien. No hay manera, es p < 0,05 para ambos parámetros

Presentación

http://www.tigenix.com/public/uploads/files/2015/slidedeck/20150915-tigenix-corporate-presentation-v2.pdf

Resultados del primer semestre

http://www.tigenix.com/public/uploads/files/2015/2015documents/20150915-tigenix-hy-results.pdf

«Después de nada, o después de todo/ supe que todo no era más que nada.»